The effect of initial dose of thyroxine in congenital hypothyroidism on final height

C. Brook

DOI: https://doi.org/10.1046/j.1365-2265.1997.3151111.x

1997-12-01

Clinical Endocrinology

Abstract:The major outstanding issue in the management of congenital hypothyroidism is the size of the dose for the initiation of therapy which will be optimal in terms of outcome. Generally, this outcome has focused on intellectual attainment. It is generally well accepted that the major determinant is the degree of hypothyroidismin utero, which has irreversible effects on intellectual outcome. Recent data (Dubuis et al., 1996) suggest that the developmental gap between children with severe and moderate congenital hypothyroidism can be closed by early high-dose thyroxine therapy. However, not all studies have come to the same conclusion (Campos et al., 1995), and there is anxiety that high doses may be associated with an increase in behaviour problems, even if they induce a higher intelligence quotient (Rovet & Ehrlich 1995). For me, the bearing which the data reported by Dickerman & DeVries (1997) have on this issue, and their implication for the control of normal growth, is the major interest of their paper. Nobody had any real doubt that growth and pubertal development could be normalised by treatment in patients with congenital hypothyroidism, but the reporting of an association between the average daily dose of thyroxine administered in the first six months of treatment and the attained adult height is important but surprising for two reasons. First, it does have some relevance, albeit not critical, to the debate outlined above, but secondly, it has considerable importance for those of us interested in the control processes of human growth. It has largely been agreed that the infancy component of growth, which extends from the fetal period to the first 200 days of extrauterine life, is (almost) exclusively controlled by nutrition. Babies are born large or small according to their intrauterine environment and the growth of weanling animals is susceptible chiefly to changes in feeding (Widdowson & McCance, 1960). Indeed, the BSE crisis may stem from the realisation of farmers that they can promote growth in young animals by high-protein, high-energy forcefeeding at this time of life. Children born with congenital hypothyroidism or congenital panhypopituitarism are not small at birth and the short stature consequent upon idiopathic isolated growth hormone (GH) insufficiency does not usually become manifest until the second year of life. Exuberant growth hormone secretion does not seem to have much effect until this time either (Moranet al., 1990), so the tantalising question posed by these data is why the dose of thyroxine during the first six months affected final adult height, even if the magnitude of the effect was not very strong. Thyrotoxicosis is associated in children with tall stature and hypothyroidism with small stature. It has been assumed from the results of testing GH secretion in the latter instance that the short stature is translated through GH secretion. It has not generally been thought to be associated with food intake, even though increased appetite is characteristic of thyrotoxicosis, because children becoming obese in childhood do not grow excessively, which is in marked contrast to those becoming obese in the infancy period (Brook, 1972). There are no data on the calorie intake of children with hypothyroidism acquired during childhood; they do not necessarily have to eat more to become fat if they become inactive. This new finding suggests to me that a high initial dose of thyroxine for the treatment of congenital hypothyroidism probably causes an increased calorie intake which results in an acceleration of growth. What is really interesting is that, unlike the tall stature of obese children, which is not translated into an increased final height (Lloyd et al., 1961), it seems to have a lasting effect in this instance. The question which remains is why?